Actinic Keratosis Treatment Goes High-Tech As Cutting-Edge Solutions Entering the Market

Precancerous skin lesions, also known as solar keratoses or actinic keratosis (AK), are caused by long-term sun exposures and occur on the epidermis. These lesions can develop into cancerous lesions. This is why treating these medical issues is important to prevent skin cancer. This gives context to the global actinic keratosis market’s growth. It is most common on the neck, cheeks, lips, and ears. 

Demand development is driven by the rising incidence of actinic keratosis, the increased adoption of minimally invasive treatments, adequate medical coverage, and the growing number of geriatric populations. The patient’s reaction has been stronger due to the better medical reimbursement environment. Many healthcare providers now offer prescription coverage for select procedures for actinic keratosis. These policies have been a boon for both patients and healthcare providers.

According to Market.us’ research, “The Actinic Keratosis Treatment Market was valued at USD 4,252.68 million in 2022. It is expected to grow at a CAGR of 5.84% between 2023 and 2032.”

Gaurav Yadav, senior research analyst at market.us said, ” The key factor driving the rapid transition from glaucoma medications to minimally invasive surgeries for glaucoma is the actinic-keratosis market growth is its ability to transform quickly. Actinic keratosis market growth will also be driven by the introduction of advanced technological products, rising awareness, and increased research and development activities.”

Demand growth is expected to be driven by the rising incidence of actinic Keratosis, the growing acceptance of minimally invasive medical treatments, and an aging population. Patients have responded to better medical reimbursement more strongly. Many healthcare providers now offer prescription coverage for certain actinic keratosis treatments. These programs are beneficial for both patients and healthcare professionals. There are a variety of private and government awareness programs that will increase consumer awareness about the disease and its comorbidities. However, industry development will be fueled by favorable reimbursement policies which will increase affordability.

Actinic Keratosis has a bright future thanks to the upcoming introduction of new medicines and research and development of new therapies with better efficacy, convenient dosage, and lower costs. Metastases risk is reduced significantly when squamous cells carcinoma is treated early. This is a key driver for the market for actinic keratosis therapies. Actinic keratosis medicine demand is increasing as people become more aware of its harmful effects. Non-profit organizations and government agencies have launched public awareness campaigns to encourage the growth of Actinic Keratosis Treatment market.

It is expected to outperform both the former and the latter over the evaluation period. This can be partly attributed to the efficiency, speed of outcomes, and ease of using procedures.

The actinic Keratosis market can be divided into imiquimod cream and fluorouracil crème, Ingenol Mebutate gel, and fluorouracil gel. Actinic Keratosis is divided into drug and procedure segments based on their type. The market share held by the procedural segment.

The industry can be divided into hospitals and oncology centers, dermatology clinics or outpatient surgery centres based on end-users. Hospitals and oncology centers are expected to continue being very lucrative in 2023 and beyond. This is due to their high patient count. Over the forecast period, hospitals and oncology centers will hold a dominant market share for actinic Keratosis in the global market. Dermatology diagnostic clinics will emerge as another important segment of the actinic Keratosis industry.

Actinic keratosis market growth is limited by insufficient reimbursement and high treatment costs. Market growth will also be impeded by a shortage of surgeons to perform the surgery.